The market for weight-loss drugs is heating up as Novo Nordisk, the maker of Wegovy, takes legal action against telehealth companies like Hims & Hers for offering compounded versions of its popular medication. This comes as analysts see a p...
GLP-1 wars: Wegovy maker challenges knock-off weight loss drug companies
Online telehealth company Hims & Hers is set to launch a copy of the Wegovy pill for $49, significantly undercutting Novo Nordisk’s $149 branded version. This announcement has sent shockwaves through the pharmaceutical market, impacting the...
Novo Shares Fall As Hims & Hers Offers $49 Wegovy Copycat
This article examines the investment potential of Hims & Hers Health, Inc. (HIMS) and Okta, Inc. (OKTA), analyzing their growth strategies, recent performance, and key market factors influencing their stock trends. Both companies represent...
Hims & Hers Health (HIMS) is venturing into GLP-1 microdosing treatments, sparking interest and debate in the telehealth and weight management sectors. This move coincides with the company's upcoming Q3 earnings report, adding to the market...
Hims & Hers Health (HIMS): Exploring Valuation as Q3 Earnings and GLP-1 Launch Boost Market Activity
Hims & Hers Health, Inc. (HIMS) recently experienced a stock decline that surpassed the losses seen in the broader market. This article breaks down the factors influencing this downturn and what investors should consider.
Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market
Shares of Hims & Hers Health (HIMS) experienced a surge following the announcement of new perimenopause and menopause treatment options. This move signals a significant expansion into women's health, offering personalized treatment plans an...
Hers Launches Menopause and Perimenopause Specialty, Taking the Next Step Toward $1B of Hers Revenue in 2026
Hims & Hers Health (HIMS) has experienced significant stock fluctuations recently. This article examines the factors driving these movements, including insider trading activity, hedge fund positions, analyst ratings, and regulatory challeng...
$HIMS stock is down 8% today. Here's what we see in our data.
Hims & Hers Health, Inc. (HIMS) has seen significant activity in institutional investment and insider trading, alongside mixed analyst ratings. This article provides a recap of these developments, offering insights for investors monitoring...
Dakota Wealth Management Takes Position in Hims & Hers Health, Inc. $HIMS
An analysis of Hims & Hers Health (HIMS) stock, examining its recent market performance, future growth prospects, and overall investment appeal. The stock's movements are contextualized within broader market trends and industry benchmarks.
Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: Here's Why
Recent market activity has been marked by mixed results. Hims & Hers Health saw its stock decline after a revenue miss, while the S&P 500 rebounded strongly. ThredUp experienced a surge following a Q2 earnings beat. Here's a quick recap com...
This week's market activity is influenced by Hims & Hers' upcoming earnings report, Nio's struggles in the Chinese EV market, and American Eagle's controversial ad campaign. Each of these events is driving significant attention and market m...
All eyes are on Hims’ weight-loss biz ahead of Monday earnings
Hims & Hers Health, Inc. (HIMS) has garnered significant investor interest due to its impressive growth and market performance. This article examines the factors driving HIMS's stock trend and provides insights into its potential future.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Hims & Hers Health, Inc. (HIMS) has emerged as a significant player in the telehealth industry, experiencing both rapid growth and notable challenges. From its founding in 2017 to its current position, the company has redefined personal wel...
Here's Why Hims & Hers Health, Inc. (HIMS) is a Strong Momentum Stock
Wall Street analysts are closely watching healthcare stocks for growth potential and resilience. This article compares Hims & Hers Health (HIMS), Eli Lilly (LLY), and Tempus AI (TEM) to identify which stock analysts favor right now.
HIMS vs. LLY vs. TEM: Which Healthcare Stock Is Wall Street’s Top Buy Right Now?
Hims & Hers Health (HIMS) has experienced significant stock volatility in 2025, marked by dramatic swings from approximately $25 to over $70 and back down. Despite the turbulence, the stock has demonstrated over 120% year-to-date growth, po...
Why Hims & Hers Health Stock (HIMS) Is Too Hot to Handle
Hims & Hers Health, Inc. (NYSE: HIMS) has reported outstanding financial results for Q1 2025, demonstrating substantial growth and profitability. The company's revenue surged by 111% compared to the previous year, reaching $586 million. Thi...
Hims Earnings Reveal Massive 111% Growth as Digital Health Platform Targets $6.5B Revenue by 2030
Hims & Hers Health (NYSE:HIMS) is set to release its Q1 2025 financial results, marking a significant milestone in its evolution from a men's health startup to a comprehensive, consumer-driven healthcare platform. Analysts are keenly watchi...
How Will HIMS Stock React To Its Upcoming Earnings?
Hims & Hers Health, Inc. (HIMS) is making waves in the telehealth industry. Known for providing accessible health and wellness solutions directly to consumers, the company has recently been the subject of both positive and critical analysis...
Breaking Down Hims & Hers Health: 13 Analysts Share Their Views